## Joan D Beckman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1391076/publications.pdf Version: 2024-02-01



IOAN D RECKMAN

#	Article	IF	CITATIONS
1	Microfluidic Methods to Advance Mechanistic Understanding and Translational Research in Sickle Cell Disease. Translational Research, 2022, , .	5.0	0
2	Soluble MD-2 and Heme in Sickle Cell Disease Plasma Promote Pro-Inflammatory Signaling in Endothelial Cells. Frontiers in Immunology, 2021, 12, 632709.	4.8	8
3	Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2021, 16, 304-313.	2.3	14
4	High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. Blood Cancer Journal, 2021, 11, 96.	6.2	4
5	Adult Langerhans histiocytosis with rare BRAF mutation complicated by massive pulmonary embolism. Thrombosis Research, 2020, 193, 207-210.	1.7	1
6	Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding. Orphanet Journal of Rare Diseases, 2020, 15, 185.	2.7	11
7	Gastrointestinal metastatic breast cancer unmasked by anticoagulation. Current Problems in Cancer Case Reports, 2020, 1, 100002.	0.1	2
8	Hematocrit and incidence of venous thromboembolism. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 422-428.	2.3	13
9	Endothelial TLR4 Expression Mediates Vaso-Occlusive Crisis in Sickle Cell Disease. Frontiers in Immunology, 2020, 11, 613278.	4.8	20
10	Ruxolitinib Reduces Endothelial Pro-Adhesive Interactions: Implications for JAK2V617+ MPN Thrombosis. Blood, 2020, 136, 1-1.	1.4	3
11	Mechanistic rationale for factor XIII cotreatment in haemophilia. Haemophilia, 2019, 25, e377-e378.	2.1	3
12	Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease. Blood, 2019, 133, 2529-2541.	1.4	51
13	Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin αâ€chain crosslinking. Journal of Thrombosis and Haemostasis, 2018, 16, 131-141.	3.8	6
14	Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura. American Journal of Therapeutics, 2018, 25, e270-e272.	0.9	19
15	Challenges in diagnosis and management of acquired factor XIII (FXIII) inhibitors. Haemophilia, 2018, 24, e417-e420.	2.1	10
16	Mechanism Underlying a Role for Factor XIII (FXIII) Polymorphism in Sickle Cell Disease-Associated Priapism. Blood, 2018, 132, 2361-2361.	1.4	0
17	Elevated hematocrit enhances platelet accumulation following vascular injury. Blood, 2017, 129, 2537-2546.	1.4	90
18	Co-Administration of Factor XIII with Hemostatic Agents in Hemophilia Promotes Clot Stability and Composition. Blood, 2016, 128, 2589-2589.	1.4	0

JOAN D BECKMAN

#	Article	IF	CITATIONS
19	Effect of Genotype and Antifibrinolytic Therapy on the Severity of Epistaxis in Hereditary Hemorrhagic Telangiectasia. Blood, 2014, 124, 1515-1515.	1.4	0
20	Regulation of Heme Oxygenase-1 Protein Expression by miR-377 in Combination with miR-217. Journal of Biological Chemistry, 2011, 286, 3194-3202.	3.4	76
21	Carbon Monoxide Therapy Modulates Hematopoietic Stem Cell Development in Heme-Oxygenase-1 Knockout Mice. Blood, 2011, 118, 1318-1318.	1.4	0
22	Heme oxygenase-1 gene delivery by Sleeping Beauty inhibits vascular stasis in a murine model of sickle cell disease. Journal of Molecular Medicine, 2010, 88, 665-675.	3.9	77
23	Heme Degradation and Vascular Injury. Antioxidants and Redox Signaling, 2010, 12, 233-248.	5.4	196
24	Carbon Monoxide Therapy Reduces Reactive Oxygen Species Production and the Short-Term Hematopoietic Stem Cell Population In Heme-Oxygenase-1 Knockout Mice. Blood, 2010, 116, 4767-4767.	1.4	0
25	Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H1243-H1253.	3.2	47
26	Heme Oxygenase-1 Gene Therapy in a Murine Model of Sickle Cell Disease Blood, 2009, 114, 1527-1527.	1.4	0
27	Quantitative real-time polymerase chain reaction (qRT-PCR) restriction fragment length polymorphism (RFLP) method for monitoring highly conserved transgene expression during gene therapy. Translational Research, 2008, 152, 290-297.	5.0	4
28	Potential Role of Heme Oxygenase-1 in Arsenic Trioxide and Hemin-Mediated Differentiation of Human Promyelocytic Leukemia Cells. Blood, 2008, 112, 3981-3981.	1.4	0
29	Carbon Monoxide Decreases Leukocytosis in Murine Sickle Cell Disease Models Via Decreased Granulopoiesis Blood, 2008, 112, 1433-1433.	1.4	0
30	Isolation and Characterization of Ovine Luteal Pericytes and Effects of Nitric Oxide on Pericyte Expression of Angiogenic Factors. Endocrine, 2006, 29, 467-476.	2.2	28
31	Transition of Human Embryonic Stem Cell-Derived Endothelial Cells to Smooth Muscle Cells in Culture as a Model for Vascular Development Blood, 2005, 106, 3683-3683.	1.4	0
32	Targeted sequencing of candidate gene regions for myelofibrosis in dogs. Journal of Veterinary Internal Medicine, 0, , .	1.6	2